These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32389673)

  • 1. Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma.
    Henning C; Meyers S; Swift R; Eades B; Bussell L; Spektor TM; Berenson JR
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e492-e495. PubMed ID: 32389673
    [No Abstract]   [Full Text] [Related]  

  • 2. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
    Woo TE; Kuzel P
    Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
    Riahi A; Lam JM
    Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
    Paton DM
    Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
    Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
    Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crisaborole 2% Ointment (Eucrisa
    Gupta AK; Versteeg SG; Abramovits W; Vincent KD
    Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
    [No Abstract]   [Full Text] [Related]  

  • 9. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriasis with crisaborole.
    Lee EB; Lebwohl MG; Wu JJ
    J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating crisaborole as a treatment option for atopic dermatitis.
    Ramachandran V; Cline A; Feldman SR; Strowd LC
    Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis.
    Castelli G; Schaffer M
    Am Fam Physician; 2018 Sep; 98(6):379-380. PubMed ID: 30215912
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
    Purohit V; Riley S; Tan H; Ports WC
    J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
    Cheape AC; Murrell DF
    Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-Label Therapeutic Potential of Crisaborole.
    Makins C; Sanghera R; Grewal PS
    J Cutan Med Surg; 2020; 24(3):292-296. PubMed ID: 32133868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin.
    Kim M; Del Duca E; Cheng J; Carroll B; Facheris P; Estrada Y; Cha A; Werth J; Bissonnette R; Nocka K; Zang C; Pavel AB; Guttman-Yassky E
    J Am Acad Dermatol; 2023 Aug; 89(2):283-292. PubMed ID: 37054814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review.
    Kahn JS; Grossman-Kranseler JS; Zancanaro P; Griffiths D; Dumont N; Rosmarin D
    Dermatitis; 2021 Nov-Dec 01; 32(6):e141-e143. PubMed ID: 34570730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.